Cargando…
Selective inhibition of mTORC1 in tumor vessels increases antitumor immunity
A tumor blood vessel is a key regulator of tissue perfusion, immune cell trafficking, cancer metastasis, and therapeutic responsiveness. mTORC1 is a signaling node downstream of multiple angiogenic factors in the endothelium. However, mTORC1 inhibitors have limited efficacy in most solid tumors, in...
Autores principales: | Wang, Shan, Raybuck, Ariel, Shiuan, Eileen, Cho, Sung Hoon, Wang, Qingfei, Brantley-Sieders, Dana M., Edwards, Deanna, Allaman, Margaret M., Nathan, James, Wilson, Keith T., DeNardo, David, Zhang, Siyuan, Cook, Rebecca, Boothby, Mark, Chen, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455083/ https://www.ncbi.nlm.nih.gov/pubmed/32759497 http://dx.doi.org/10.1172/jci.insight.139237 |
Ejemplares similares
-
Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis
por: Morrison Joly, Meghan, et al.
Publicado: (2017) -
Oncogenic Functions and Therapeutic Targeting of EphA2 in Cancer
por: Wilson, Kalin, et al.
Publicado: (2021) -
mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016) -
Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension
por: Tang, Haiyang, et al.
Publicado: (2018) -
Host deficiency in ephrin-A1 inhibits breast cancer metastasis
por: Shiuan, Eileen, et al.
Publicado: (2020)